^
    4ms
    A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). (clinicaltrials.gov)
    P1, N=113, Active, not recruiting, Chugai Pharmaceutical | Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Sep 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    SPYK04
    1year
    A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). (clinicaltrials.gov)
    P1, N=113, Recruiting, Chugai Pharmaceutical | Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS mutation • BRAF mutation • RAS mutation
    |
    SPYK04
    4years
    A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). (clinicaltrials.gov)
    P1, N=90, Recruiting, Chugai Pharmaceutical | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS mutation • BRAF mutation
    |
    SPYK04
    over4years
    A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). (clinicaltrials.gov)
    P1, N=90, Not yet recruiting, Chugai Pharmaceutical
    Clinical • New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS mutation • BRAF mutation
    |
    SPYK04